|Bid||1.3500 x 2900|
|Ask||1.3600 x 1400|
|Day's range||1.2400 - 1.3900|
|52-week range||0.6300 - 8.4000|
|Beta (5Y monthly)||1.97|
|PE ratio (TTM)||N/A|
|Earnings date||04 Aug 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||1.00|
The Company has made plans for a smooth transition. Mr. Weinstein is a finance and accounting senior executive with over 30 years of “hands-on” public and private company management, investment banking and private equity investing experience.
Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.
Align Technology (ALGN) succeeds in consecutively delivering a solid spurt in Invisalign Technology volumes across the company's entire clientele.
This latest FDA approval of Medtronic's (MDT) Evolut PRO+ follows the last month's nod from the regulatory body for the Evolut TAVR system with regard to expanded indication.
With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.
Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.
Zimmer Biomet (ZBH) prepares for the commercial launch of improvised knee replacement procedures through its flagship program, Persona Revision Knee System.
Vancouver, Canada, Aug 19, 2019 - (ABN Newswire) - Join Ellis Martin for an exclusive conversation pertinent to the world of the disruptive disease called Alzheimers. Is there a cure for Alzheimers? An American biotech company called Neurotrope (NAS:NTRP - News) believes it has this proprietary platform technology with a natural compound from the depths of the ocean that they've developed called Bryostatin.